<DOC>
	<DOCNO>NCT01908933</DOCNO>
	<brief_summary>The purpose study prospectively evaluate safety efficacy AeriSeal System patient advance Non-Upper Lobe Predominant Heterogeneous Emphysema .</brief_summary>
	<brief_title>Study AeriSeal System Treatment Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema</brief_title>
	<detailed_description>This prospective single arm study evaluate safety efficacy AeriSeal System patient advance Non-Upper Lobe Predominant Heterogeneous Emphysema .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Willing able provide inform consent participate study Age &gt; = 40 year time screen Advanced low low upper lobe predominant heterogeneous emphysema CT scan Minimum 2 subsegments appropriate treatment MRCD questionnaire score 2 great screening Failure medical therapy provide relief symptom Spirometry 15 minute administration bronchodilator ( BOTH ) : FEV1 &lt; 50 % predict . FEV1/FVC ratio &lt; 70 % Lung volume plethysmography ( BOTH ) : Total Lung Capacity ( TLC ) &gt; 100 % predict Residual Volume ( RV ) &gt; 150 % predict Diffusing Capacity Carbon Monoxide ( DLco ) &gt; = 20 &lt; = 60 percent predict Oxygen saturation ( SpO2 ) &gt; 90 % &lt; = 4 L/min supplemental O2 , rest SixMinute Walk Test distance &gt; = 150 Abstinence smoking least 16 week prior screen Prior lung volume reduction surgery , prior lobectomy pneumonectomy , prior lung transplantation Requirement ventilator support ( invasive noninvasive ) Three ( 3 ) COPD exacerbation require hospitalization within 1 year Screening visit COPD exacerbation require hospitalization within 8 week Screening visit Pulmonary hypertension , define : Echocardiogram estimate peak systolic pressure &gt; 45 mmHg presence tricuspid valve regurgitation state echocardiogram report If echocardiogram show peak systolic pressure &gt; 45 mmHg , right heart catheterization require rule pulmonary hypertension , define peak systolic pressure &gt; 45 mmHg mean pressure &gt; 35 mmHg Clinically significant asthma ( reversible airway obstruction ) bronchiectasis CT scan : Presence follow radiologic abnormality : Pulmonary nodule CT scan great 1.0 cm diameter ( Does apply present 2 year without increase size proven benign biopsy/PET ) Radiologic picture consistent active pulmonary infection , e.g. , unexplained parenchymal infiltrate Significant interstitial lung disease Significant pleural disease Giant bullous disease ( predominant bulla &gt; 10 cm dimension &gt; 1 / 3 hemithorax ) Use systemic steroid &gt; 20 mg/day equivalent , immunosuppressive agent , heparin , oral anticoagulant ( e.g. , warfarin , dicumarol ; note : antiplatelet drug include aspirin clopidogrel permit ) Allergy sensitivity medication require safely undergo AeriSeal System treatment Participation investigational study drug , biologic , device currently approve marketing within 30 day prior screen visit Body mass index &lt; 15 kg/m2 &gt; 35 kg/m2 Female patient pregnant breastfeed planning pregnant next year Significant comorbidity carry prohibitive risk associate less 2year expect survival , include follow : HIV/AIDS Active malignancy Stroke Transient Ischemia Attack ( TIA ) within 12 month screen Myocardial infarction within 12 month screen Congestive heart failure within 12 month screen define clinical evidence right leave hear failure leave ventricular ejection fraction &lt; 45 % echocardiogram Any condition Investigator believe would interfere intent study would make participation best interest patient alcoholism , high risk drug abuse noncompliance return followup visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Advanced Emphysema</keyword>
	<keyword>Heterogeneous Lower Lobe Predominant Emphysema</keyword>
	<keyword>Heterogeneous Upper Lower Lobe Predominant</keyword>
</DOC>